SCHEMBL6028964

SCHEMBL6028964

[CH2]Cc1ccccc1-c1cccs1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.61
DPP4 P27487 2/20 0.38
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
ATM Q13315 1/20 0.38
LTK P29376 1/20 0.38
CDK5 Q00535 1/20 0.38
MST1R Q04912 1/20 0.38
DYRK1A Q13627 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
HPGD P15428 2/20 0.37
LMNA P02545 1/20 0.37
TDO2 P48775 1/20 0.37
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MAOB P27338 1/20 0.37
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092144 0.90 LTA4H (0.49) LTA4HDPP4RAB9ANPC1ATM
SCHEMBL4848749 0.80 LTA4H (0.61) LTA4HDPP4RAB9ANPC1ATM
SCHEMBL4845248 0.80 LTA4H (0.61) LTA4HDPP4RAB9ANPC1ATM
SCHEMBL477614 0.80 LTA4H (0.61) LTA4HDPP4RAB9ANPC1ATM
SCHEMBL4846964 0.80 LTA4H (0.61) LTA4HDPP4RAB9ANPC1ATM
SCHEMBL3780733 0.80 LTA4H (0.61) LTA4HDPP4RAB9ANPC1ATM
SCHEMBL5023959 0.80 LTA4H (0.66) LTA4HDPP4RAB9ANPC1LTK
SCHEMBL4467348 0.79 LTA4H (0.56) LTA4HDPP4RAB9ANPC1ATM
Hydrochloric Acid SCHEMBL2463750 0.78 LTA4H (0.59) LTA4HDPP4RAB9ANPC1ATM
SCHEMBL995326 0.78 LTA4H (0.55) LTA4HRAB9ANPC1ATMLTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1601674-B1 Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders JANSSEN PHARMACEUTICA NV (BE) 2012-08-08 EP disclosed
US-7081463-B2 Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-25 US disclosed